Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.

The firm often engages with company managements and boards to improve performance and will also take passive stakes in companies with a long-term view of value creation.

Cambridge Epigenetix Raises $88 Million Series D Financing To Advance Best-In-Class Dna Sequencing Technology Platform

Description

Company Information

Funding Insights

Cambridge Epigenetix Raises $88 Million Series D Financing To Advance Best-In-Class Dna Sequencing Technology Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information